ClinicalTrials.gg
WithdrawnNCT03658213LARESUpdated May 10, 2021

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

A Phase 3 interventional study of ZOLADEX 10.8 mg and ZOLADEX 3.6mg in Breast Cancer, sponsored by AstraZeneca. Withdrawn at 11 sites in China. Open to female participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2021-05-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was withdrawn
CTP of LARES has been out of the expire date, we are trying RWS pathway for the indication expend

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.

Enrollment
40th of 41
0 · median 147
Started
2020
with 1 other
Phase 3
15 of 43
none open now
Registered
32nd of 43
by date
Lead sponsor
5 of 43
AstraZeneca

Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 40th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2020, is one of 15 in phase 3, and was the 32nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 59 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing goserelin in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will recruit 168 patients in approximately 20 study centres in China.

The primary objective of this study is to examine whether ZOLADEX 10.8 mg depot is non-inferior to ZOLADEX 3.6 mg depot in terms of the suppression rate of serum estradiol (E2) to the menopausal level (≤30 pg/mL) from Week 4 through Week 24.

Read the detailed description

This study will recruit 168 patients in approximately 20 study centres in China.

This open label, randomised, parallel group, multicentre study in Chinese pre menopausal patients with ER+/HER2- early breast cancer will be conducted to determine whether 3 monthly ZOLADEX 10.8 mg injection is non-inferior to monthly ZOLADEX 3.6 mg injection in terms of estradiol (E2) suppression. The study will also assess the PK, pharmacodynamics (PD), safety and tolerability of two difference strengths of ZOLADEX.

Eligible patients, as judged by the Investigator after completion of the screening tests, will be registered for this study and at the same time randomised in a 1:1 ratio to receive one of the following treatments. The study treatment must start within 7 days after randomisation.

  • ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks
  • ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks

The primary objective:

  • To examine whether ZOLADEX 10.8 mg depot is non-inferior to ZOLADEX 3.6 mg depot in terms of the suppression rate of serum estradiol (E2) to the menopausal level (≤30 pg/mL) from Week 4 through Week 24.

The secondary objectives:

  • To evaluate the safety and tolerability profiles of ZOLADEX 10.8 mg depot and ZOLADEX 3.6 mg depot.
  • To evaluate the estradiol (E2) suppression by assessment of area under the curve (AUC) of E2 serum concentration during the 24 weeks of treatment.
  • To evaluate the goserelin pharmacokinetics (PK) in Chinese patients after injection of ZOLADEX 10.8 mg depot and ZOLADEX 3.6 mg depot.
  • To assess the influence on menstruous condition after injection of ZOLADEX 10.8 mg depot or ZOLADEX 3.6 mg depot.
  • To assess the hormonal conditions after injection of ZOLADEX 10.8 mg depot compared with ZOLADEX 3.6 mg depot.
03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Early breast cancer
  • Goserelin acetate
  • Estrogen suppression
  • Pre-menopausal
  • Zoladex
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures.
  2. Women aged ≥18 at screening, in pre-menopausal status defined as:

    • Menses within 1 year before enrolment and within 3 weeks before enrolment, E2 >30 pg/mL and FSH ≤40 mIU/mL.
    • Patients who received neo/ chemotherapy before randomisation should not having chemical menopause (Patients should meet: E2>30pg/mL and FSH ≤40mIU/mL) within 12 weeks after completion of the postoperative chemotherapy.
  3. confirmed ER+/- primary invasive operable breast cancer (ER+ defined as at least 1% of the cells examined by immunohistochemistry testing have estrogen receptors).
  4. Neoadjuvant chemotherapy and adjuvant chemotherapy prior to study enrolment are acceptable. (Please refer to Guidelines such as NCCN Clinical practice guidelines in oncology-breast cancer and CSCO-BC breast cancer guidelines for standard protocols and dosages. Please make accurate records.).
  5. Have had proper surgery for primary breast cancer with no known clinical residual loco regional disease.
  6. World Health Organization (WHO) performance status of 0, 1, or 2.
  7. Female patients of child bearing potential and their partners, who are sexually active, must agree to the use of two highly effective forms of in combination throughout the period of taking study treatment and for at least 3 month after last dose of Zoladex or Tamoxifen which happens later, or they must totally/truly abstain from any form of sexual intercourse.

Exclusion criteria

Exclusion Criteria:

  1. Any evidence of disease.
  2. Have received other previous neo/ endocrine therapy for breast cancer.
  3. Other within the last 3 years except adequately treated basal cell/squamous cell carcinoma of the skin or cancer of the cervix.
  4. Have any unstable complication or uncontrolled infection during screening.
  5. Patients considered at poor medical risk due to a serious, uncontrolled medical disorder, non malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, extensive bilateral lung disease on High Resolution Computed Tomography scan or any psychiatric disorder that prohibits obtaining .
  6. woman, defined as a woman fulfilling any of the following criteria:

    • Having undergone a bilateral oophorectomy
    • Age ≥60 years
    • Age \<60 years and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression and FSH and oestradiol level in the postmenopausal range (utilising ranges from the local laboratory facility)
    • If taking tamoxifen or toremifene, and age \< 60 years, then FSH and plasma oestradiol level in the postmenopausal ranges (utilising ranges from the local laboratory facility)
  7. Have had a bilateral oophorectomy or ovarian irradiation.
  8. overexpression or gene amplification, i.e., immunohistochemistry (IHC)3+ or fluorescence in situ hybridisation (FISH)+, where appropriate
  9. Screening test results of:

    • \<100 × 109/L
    • Total >1.5 × upper limit reference range (ULRR)
    • (ALT) or Aspartate aminotransferase (AST) >2.5 × ULRR
  10. Any other significantly abnormal laboratory test result at screening that would place the patient at unusual risk or confound the results of the study.
  11. Patients with a relevant history of any severe concomitant disease that would place the patient at unusual risk or confound the results of the study, e.g., a strong family history of osteoporosis or severe renal or hepatic impairment.
  12. Patients who, for whatever reason (e.g., confusion, infirmity, alcoholism) are unlikely to comply with study requirements as judged by the Investigator(s).
  13. Patients considered by the Investigator(s) to be at risk of transmitting any infection through blood or other body fluids including the agents for acquired-immune deficiency syndrome (AIDS) or other sexually transmitted disease or hepatitis.
  14. History of bleeding diathesis (i.e., disseminated intravascular coagulation [DIC] or clotting factor deficiency) or long-term anti-coagulant therapy (other than anti platelet therapy and low dose warfarin).
  15. History of any to active or inactive of LHRH agonist or tamoxifen.
  16. Patients unwilling to stop taking any drug that affects sex hormonal status, or in whom it would be inappropriate to stop.
  17. Participation in another clinical study with an product during the last 30 days.
  18. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study centre).
  19. Previous enrolment or randomisation of treatment in the present study.
  20. Female patients who are pregnant or breast-feeding.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    ZOLADEX 10.8 mg depot group

    • ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks

    Drug: ZOLADEX 10.8 mg

  • Active comparator
    ZOLADEX 3.6 mg depot group

    • ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks

    Drug: ZOLADEX 3.6mg

Interventions

  • 10.8 mg depot for injection (equivalent to 10.8 mg goserelin)

    Also known as: ZOLADEX® (goserelin acetate implant) 10.8 mg

  • 3.6 mg depot for injection (equivalent to 3.6 mg goserelin)

    Also known as: ZOLADEX® (goserelin acetate implant) 3.6 mg

06

What researchers measure

Primary outcomes

  1. Effective inhibition rate of serum estradiol(E2)

    Percentage of participants with suppressive effect of mean serum estradiol (E2) (from 4th week to 24th week) to menopausal level (≤30 pg/mL).

    Time frame: At scheduled visits from Week 4 through Week 24.

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    All AE data will be listed and the treatment-emergence status will be flagged in the listing.

    Time frame: From screening to 4 weeks after the completion of 24 weeks treatment period.

  2. Change in Alanine aminotransferase(U/L)

    Data for Alanine aminotransferase recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  3. Change in Aspartate aminotransaminase(U/L)

    Data for Aspartate aminotransaminase recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  4. Change in Albumin(g/L)

    Data for Albumin recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  5. Change in Alkaline phosphatase(U/L)

    Data for Alkaline phosphatase recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  6. Change in Calcium(mmol/L)

    Data for Calcium recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  7. Change in Creatinine(μmoI/L)

    Data for Creatinine recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  8. Change in High density lipoprotein cholesterol(mmol/L)

    Data for High density lipoprotein cholesterol recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  9. Change in Inorganic phosphate(mmol/L)

    Data for Inorganic phosphate recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  10. Change in Low density lipoprotein cholesterol(mmol/L)

    Data for Low density lipoprotein cholesterol recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  11. Change in Plasma glucose(mmol/L)

    Data for Plasma glucose recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  12. Change in Potassium(mmol/L)

    Data for Potassium recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  13. Change in Lactate dehydrogenase(U/L)

    Data for Lactate dehydrogenase recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  14. Change in Triglyceride(mmol/L)

    Data for Triglyceride recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  15. Change in Sodium(mmol/L)

    Data for Sodium recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  16. Change in Total bilirubin(μmol/L)

    Data for Total bilirubin recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  17. Change in Total cholesterol(mmol/L)

    Data for Total cholesterol recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  18. Change in Absolute neutrophil count(/L)

    Data for Absolute neutrophil count recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  19. Change in Haematocrit(vol%)

    Data for Haematocrit recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  20. Change in Haemoglobin(g/L)

    Data for Haemoglobin recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  21. Change in Mean cell volume(fl)

    Data for Mean cell volume recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  22. Change in Platelet count(/L)

    Data for Platelet count recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  23. Change in White blood cell count (total)(/L)

    Data for White blood cell count (total) recorded in the eCRF will be listed and summarized by treatment group and visit.

    Time frame: At scheduled visits from screening to 24th week.

  24. Change in Systolic Blood Pressure(mmHg)

    Actual data and changes from baseline in Systolic blood pressure will be summarized by visit using descriptive statistics.

    Time frame: At scheduled visits from screening to 24th week.

  25. Change in Diastolic blood pressure(mmHg)

    Actual data and changes from baseline in Diastolic blood pressure will be summarized by visit using descriptive statistics.

    Time frame: At scheduled visits from screening to 24th week.

  26. Change in Heart rate(bpm)

    Actual data and changes from baseline in Heart rate will be summarized by visit using descriptive statistics.

    Time frame: At scheduled visits from screening to 24th week.

  27. To evaluate the estradiol (E2) suppression by assessment of area under the curve (AUC) of E2 serum concentration.

    Area under the curve (AUC) of E2 serum concentration during 24 weeks of treatment

    Time frame: At scheduled visits from screening to 24th week.

  28. Observed maximum Goserelin plasma concentration (Cmax)

    Only for PK subgroup; derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug.

    Time frame: At scheduled visits from treatment start to treatment completion (week 24th).

  29. Time to maximum Goserelin plasma concentration (tmax)

    Only for PK subgroup; derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug.

    Time frame: At scheduled visits from treatment start to treatment completion (week 24th).

  30. Area under the Goserelin plasma concentration-time curve from time zero to time of the last measurable concentration (AUCt)

    Only for PK subgroup; derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug.

    Time frame: At scheduled visits from treatment start to treatment completion (week 24th).

  31. Area under the Goserelin plasma concentration-time curve from time zero to 4 weeks (AUC (0-4 weeks))

    Only for 3.6 mg PK subgroup; derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug.

    Time frame: At scheduled visits from treatment start to 4 Weeks.

  32. Area under the Goserelin plasma concentration-time curve from time zero to 12 weeks (AUC (0-12 weeks))

    Only for 10.8 mg PK subgroup; derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug.

    Time frame: At scheduled visits from treatment start to 12 Weeks.

  33. Trough concentration (Ctrough)

    Goserelin plasma concentration of pre-dose sample during multiple dose period.

    Time frame: At scheduled visits from treatment start to treatment completion (24th week).

  34. The rate of participants who had menstruation.

    The proportion of subjects who had menstruation at each time point will be summarized by treatment group.

    Time frame: At scheduled visits from screening to treatment completion (24th week), approximately 27 weeks.

  35. E2 serum concentrations

    E2 concentration at each visit will be listed and summarized for each treatment group using descriptive statistics. Mean E2 concentration versus time plots and individual FSH concentration versus time plots will be presented.

    Time frame: At scheduled visits from screening to treatment completion (24th week), approximately 27 weeks.

  36. FSH serum concentrations

    FSH concentration at each visit will be listed and summarized for each treatment group using descriptive statistics. Mean FSH concentration versus time plots and individual FSH concentration versus time plots will be presented.

    Time frame: At scheduled visits from screening to treatment completion (24th week), approximately 27 weeks.

07

Study locations

11 sites
  • Research Site
    Beijing, 100006, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Shijiazhuang, 050035, China
  • Research Site
    Tianjin, 300060, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2020; primary completion for Nov 2021, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2018
First posted
Sep 5, 2018
StartEst.
Mar 31, 2020
Primary completionEst.
Nov 4, 2021
CompletionEst.
Nov 4, 2021
Last update
May 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03658213
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 5, 2018
Start date
Mar 31, 2020 (estimated)
Primary completion
Nov 4, 2021 (estimated)
Completion
Nov 4, 2021 (estimated)
Last update
May 10, 2021

Study contacts

Zefei JIANG
principal investigator · 307 Hospital of PLA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion